N/A N=510 Promoting Altruism to Enhance Vaccine Acceptance
Vaccine Refusal
Primary: Change in Vaccine Hesitancy Scores Pre- and Post-Intervention. — -0.4 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=544 Feasibility of Cocooning Immunization Strategy With Influenza Vaccine
Influenza
Primary: Influenza Vaccine Coverage (Percent) for New Mothers of Newborns — 70; 64 Percentage of Participants
N/A N=60 VISTA: Vaccinator-Initiated Screening and TAilored Counseling for Reducing Vaccine Hesitancy
Vaccination Uptake
Primary: Percentage of Women With Reduced Number of Concerns Immediately Post-counseling in the Intervention Arm — 51.72 percentage of women
N/A N=7,879 Education Bundle to Decrease Patient Refusal of VTE Prophylaxis
Venous Thromboembolism · Deep Venous Thrombosis · Pulmonary Embolism
Primary: Percentage of Non Administration of Prescribed VTE Prophylaxis Medication Doses — 9.1; 13.6; 5.6; 13.3 Percentage of nonadministration — p=<0.05
N/A N=2,868 Increasing Vaccine Uptake Among Adolescents in the Rural South
Vaccine Hesitancy
Primary: Difference in the Percentage of Adolescents Who Ever Received at Least One Dose of HPV Vaccination in the Intervention Group After the Intervention Implementation…
Phase 3 N=1,054 A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)
Papillomavirus Infections
Primary: Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 — 1637.9; 1725.0; 1170.3; 1212.6 milli Merck…
N/A N=562 Screening for Hesitancy to Optimize Talk
Preventive Health Services
Primary: Child's Mean Percent Days Under-immunized — 19.1; 25.2 percentage of days under-immunized — p=.29
N/A N=17,446 Presumptively Initiating Vaccines and Optimizing Talk With Motivational Interviewing (PIVOT With MI)
Preventive Health Services (PREV HEALTH SERV)
Primary: Child Immunization Status at 19 Months, 0 Days of Age Characterized as Percent Days Under-immunized (DUI) — 32; 24 percentage of days under-immunized — p=0.9
N/A N=70 Vax Facts Human Papillomavirus (HPV): Study of a Computer-based Tailoring System and Mothers' Intentions to Vaccinate Their Daughters Against HPV
Human Papillomavirus · Prevention
Primary: Mother's Intention to Vaccinate Daughter Against HPV — 1.53; 1.29 units on a scale
Phase 4 N=292 Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home
Influenza
Primary: Number of Participants Who Received Influenza Vaccine. — 250 participants
N/A N=756 Views on COVID-19 and Vaccination
Covid19
Primary: Number of Participants Who Became Less Hesitant About the COVID-19 Vaccine After Receiving a Physician Message — 23; 26; 43; 35 Participants
N/A N=338,718 Developing and Testing a COVID-19 Vaccination Acceptance Intervention
COVID-19 Vaccination
Primary: Receipt of Any Dose COVID-19 Vaccination — 57621; 65407 Participants — p=0.202
Phase 4 N=22 Special Access Program IMVAMUNE®
Vaccination
Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects
N/A N=148 Healthy, Immunized Communities Study
Vaccine Hesitancy · Communicable Diseases in Children
Primary: Percentage of Participants With Intent to Vaccinate Adolescent Child (Tdap, MCV, HPV) — 74.3; 83.3; 97.9; 93.0 percentage of participants
N/A N=3,076 SDH of HPV Vaccine Completion
Human Papilloma Virus
Primary: Overall HPV Vaccine Completion Rates — 1961; 1083 Participants
N/A N=200 Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting
Human Papillomavirus Infection
Primary: Geometric Mean Antibody Titers Following the Third Dose of Human Papilloma Virus (HPV) Vaccine by Virus Type and by Administration Schedule — 1894; 4221; 1773; 5623…
Phase 2 N=123 Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths
Hepatitis B
Primary: Qualitative Seroresponsiveness to Hepatitis B Surface Antigen — 41; 52; 6; 3 Participants — p=0.2954
N/A N=456 A Chatbot Intervention for Reducing HPV Vaccine Hesitancy
Cervical Cancer · Anal Cancer · Penile Cancer
Primary: Attitudes Toward HPV Vaccination — 3.86; 3.96; 3.41 score on a scale
Phase 3 N=1,412 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)
Measles · Mumps · Rubella
Primary: Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 gpELISA Units/mL — 97.3; 93.0 Percentage of participants — p=<0.001
N/A N=31,265 HPV Vaccine Communication ECHO for Primary Care Clinics
Human Papillomavirus Vaccines · Adolescent Health Services
Primary: HPV Vaccination (≥1 Dose), 11-14 Year Olds at 12 Months — 3189; 3833; 4260 Participants
N/A N=164,205 Patient Portal - Flu Reminder Recall
Influenza · Respiratory Tract Infections · Vaccines
Primary: 1.Receipt of the Annual Influenza Vaccine (Between 10/1/18 - 4/2/19) Among Index Patients. Outcomes Will be Assessed Via Vaccine Data Extraction From the Electronic…
N/A N=228,831 Precision Vaccine Promotion in Underserved Populations
Influenza · Vaccine Hesitancy
Primary: Number of Participants Vaccinated at the End of the Campaign Period — 33357; 854 Participants — p=0.216
Phase 2 N=637 Promoting Informed Choice for Breast Cancer Screening
Breast Cancer
Primary: Reactance — 2.28; 2.45; 2.55 score on a scale
N/A N=2,701 COVID-19 Vaccination Take-Up
Covid19 · Vaccination
Primary: Rate of COVID-19 Vaccination at 1 Month — 12; 4; 0; 1 Participants
N/A N=251 COVID-19 Vaccine Uptake Trial
Vaccination Refusal · COVID-19
Primary: Vaccine Uptake — 1; 3; 1; 0 Participants
N/A N=546 A Randomized Trial of Vaccine Adherence in Young Injection Drug Users
Medication Adherence · Substance Abuse, Intravenous · Risk Behavior
Primary: Vaccine Series Completion — 16; 20; 8; 10 participants
Phase 2 N=115 VSV-ZEBOV Geneva Vaccine Trial
Ebolavirus Disease
Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml
Phase 4 N=480 Immunogenicity of Hepatitis B Vaccination Among Drug Users
Hepatitis B Vaccination
Primary: Number and Rate of Participants With Anti-HBs Seroconversion at Month 7 — 142; 138; 0 Participants
N/A N=23,768 Improving COVID-19 Vaccine Uptake in Nursing Homes
COVID-19 Vaccines
Primary: Number of Residents Who Received SARS-CoV-2 Vaccine — 3083; 2994 Participants
N/A N=2,097 Exploring Changes in COVID-19 Vaccination Intentions by Prompting Altruistic Motives Using a Video Intervention
Vaccine Refusal
Primary: Post Intervention Vaccine Intentions — 54; 47; 236; 249 Participants